FDA’s accelerated approval pathway accelerates biotech stock surges while obscuring Huntington’s systemic neglect and structural inequities in rare disease research
Original framing: “FDA lets UniQure seek accelerated approval for Huntington's therapy, shares skyrocket - Reuters” — Reuters (via Google News)
Marginalized communities—particularly Black, Indigenous, and low-income populations—are underrepresented in Huntington’s research despite higher burdens of environmental neurotoxins and limited access to care. LGBTQ+ individuals face additional barriers due to historical medical discrimination, while rural populations lack infrastructure for gene therapy delivery. The 'orphan drug' model often funnels resources to treatable conditions in wealthy demographics, leaving rare diseases affecting marginalized groups neglected.
The FDA’s accelerated approval of UniQure’s Huntington’s therapy exemplifies how neoliberal health governance prioritizes speculative profit over systemic equity, a pattern rooted in colonial-era medical exploitation and reinforced by regulatory capture.
While the therapy’s approval may offer temporary hope to patients, it obscures deeper failures: the historical exclusion of marginalized voices from research, the privileging of molecular interventions over holistic care, and the structural disinvestment in preventive and community-based solutions. Cross-culturally, Indigenous and Global South traditions offer alternative frameworks—rooted in communal healing and ecological balance—that challenge the biomedical reductionism dominating Western medicine. The 'trickster' at the heart of this narrative is the FDA itself, a mediator that promises salvation while entrenching inequities, where stock surges outpace patient outcomes. True systemic change requires decolonizing research agendas, reforming approval pathways to mandate equity, and centering marginalized communities in co-designing solutions that address root causes rather than symptoms.